Skip to main content
. 2022 Aug 4;13:954268. doi: 10.3389/fimmu.2022.954268

Table 4.

Characteristics of therapeutic response for 26 included studies (SR-cGVHD)*.

Studies Study design N Response/event (n) Overall survival Median follow-up (months)
ORR ORR at 24 weeks CRR CRR at 24 weeks 6 months 12 months 24 months
Lancman, 2018 Case report 4 NA NA 1 NA 1.00 NA NA NA
Hurabielle, 2017 Retrospective 12 NA NA 0 NA NA NA NA NA
Maas-Bauer, 2020 Retrospective 23 17 NA 2 NA NA NA 0.75 30.00
Zeiser, 2022 RCT 165 NA 82 NA 11 NA NA NA NA
Ferreira, 2021 Retrospective 35 31 NA 9 NA NA NA NA 43.00
Ferreira, 2018 Case report 20 15 NA 4 NA NA NA NA 12.00
Wei, 2021 Retrospective 32 25 NA 8 NA NA NA NA 16.50
Wang, 2021 Retrospective 70 NA 52 NA 34 NA 0.66 NA 13.37
Leung, 2022 Retrospective 31 NA 26 NA 16 NA 0.94 0.81 NA
Moiseev, 2020 Prospective 43 35 NA 9 NA NA NA NA NA
González, 2018 Prospective 9 NA NA 2 NA NA NA NA NA
Kaurinovic, 2022 Retrospective 53 43 NA 28 NA NA NA NA 20.00
Maldonado, 2017 Case report 5 5 NA 1 NA NA NA NA 12.00
Maldonado, 2021 Retrospective 8 6 NA 4 NA NA NA NA NA
Schoettler, 2019 Case report 5 NA NA NA NA NA NA NA 24.00
Modi, 2018 Retrospective 46 NA 22 NA 5 NA 0.84 NA NA
Mozo, 2021 Retrospective 12 11 NA 1 NA NA NA 0.76 NA
Zeiser, 2015 Retrospective 41 35 NA 3 NA 0.97 NA NA 5.23
Abedin, 2019 Retrospective 24 20 NA 3 NA NA NA NA NA
Redondo, 2022 Retrospective 48 37 NA 7 NA NA NA 0.83 20.00
Dang, 2020 Retrospective 28 22 NA NA NA NA NA NA 5.00
Uygun, 2020 Retrospective 15 13 NA 1 NA NA NA NA NA
Gómez, 2019 Retrospective 56 32 NA 2 NA NA 0.81 NA NA
Wu, 2021 Retrospective 41 NA 29 NA 15 0.88 0.66 NA 14.90
Xue, 2021 Retrospective 36 NA 16 NA 4 NA 0.81 0.74 NA
Zhao, 2021 Retrospective 30 20 17 3 NA NA NA 0.63 10.60

CRR, complete response rate; NA, not available; ORR, overall response rate; RCT, randomized controlled trials; SR-aGVHD, steroid-refractory acute graft-versus-host disease; SR-cGVHD, steroid-refractory chronic graft-versus-host disease.

*Thirteen studies included both SR-aGVHD and SR-cGVHD analysis.